3 Tips on Valuations and Exits for Emerging Healthcare Companies
Last week, I sat on a panel session at the IMPACT 2011 Venture Summit Mid-Atlantic conference held by the Greater Philadelphia Alliance for Capital and Technologies (PACT)…
Posted by
Safeguard Insights
NuPathe Submits Zelrix NDA for the Treatment of Migraine
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
Video: James A. Datin Talks About Safeguard Scientifics’ Life Sciences Strategy
James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…
Posted by
An Overview of Our Partner Companies
Safeguard Scientifics’ strategy is to deploy capital in growth-stage companies in attractive sectors of the life sciences and technology industries. Within life sciences, we target…
Posted by
Safeguard Scientifics’ Jim Datin Discusses Biotech Investing Trends in 2010
James A. Datin, EVP and Managing Director of Safeguard Scientifics‘ Life Sciences Group, was recently interviewed by FierceBiotech, a leading industry online publication, about biotech…
Posted by
